GLIATECH, INC.

Address

GLIATECH, INC.
23420 COMMERCE PARK RD
CLEVELAND, OH, 44122

Information

DUNS:
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. NOVEL GLYCINE TRANSPORTER INHIBITORS FOR SCHIZOPHRENIA

    Amount: $93,862.00

    The glutamate/glycine NMDA receptor has been implicated in a variety of central nervous system disorders and pathological conditions. In particular, NMDA receptor hypofunction may contribute significa ...

    SBIRPhase I2002Department of Health and Human Services
  2. N/A

    Amount: $750,000.00

    N/A

    SBIRPhase II1999Department of Health and Human Services
  3. Development of Novel Chiral Cyclic Histamine H3 Agonists

    Amount: $621,379.00

    The long-term objectives are to synthesize novel cyclic and heterocyclic histamine H3 receptor agonprodrugs thereof that have improved GI absorption and CNS penetration. These agents are being develot ...

    SBIRPhase II1998Department of Health and Human Services
  4. COMBINATORIAL CONSTRUCTION OF NOVEL IMIDAZOLE LIBRARIES

    Amount: $99,832.00

    N/A

    SBIRPhase I1998Department of Health and Human Services
  5. DEVELOPMENT OF DRUGS FOR SCHIZOPHRENIA AND DEMENTIA

    Amount: $97,517.00

    N/A

    SBIRPhase I1998Department of Health and Human Services
  6. ANTIPROPERDIN AGENTS AS NOVEL ANTIINFLAMMATORIES

    Amount: $97,516.00

    N/A

    SBIRPhase I1998Department of Health and Human Services
  7. Evaluation of a Novel H3 Antagonist, GT 2016, for Add

    Amount: $721,665.00

    The long-term objectives are to develop novel histamine H3 receptor antagonists to increase wakefuland enhance cognitive abilities. The specific aims of this grant are (1) to test a novel non- thiourf ...

    SBIRPhase II1997Department of Health and Human Services
  8. INHIBITION OF POSTOPERATIVE GYNECOLOGICAL ADHESIONS

    Amount: $99,076.00

    N/A

    SBIRPhase I1997Department of Health and Human Services
  9. MOLECULAR CHARACTERIZATION--HISTAMINE RECEPTOR SUBTYPES

    Amount: $99,535.00

    N/A

    SBIRPhase I1997Department of Health and Human Services
  10. Development of Novel Chiral Cyclic Histamine H3 Agonists

    Amount: $100,000.00

    The long-term objectives are to synthesize novel cyclic and heterocyclic histamine H3 receptor agonprodrugs thereof that have improved GI absorption and CNS penetration. These agents are being develot ...

    SBIRPhase I1995Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government